In the BioHarmony Drug Report Database
Farxiga, Edistride, Forxiga (dapagliflozin) is a small molecule pharmaceutical. Dapagliflozin was first approved as Farxiga on 2012-11-11. It is used to treat type 2 diabetes mellitus in the USA. It has been approved in Europe to treat type 1 diabetes mellitus and type 2 diabetes mellitus. It is known to target sodium/glucose cotransporter 2 and sodium/glucose cotransporter 1. Farxiga’s patents are valid until 2040-03-09 (FDA).
Image (chem structure or protein)